CD274 and small cell lung carcinoma: Regarding the selection of ICIs in ES‐SCLC patients in the chemo‐immune group, 91 (55.15%) patients chose PD‐1 inhibitors, while the remaining 77 (44.85%) patients chose PD‐L1 inhibitors.